HUYABIO International Announces HBI-8000 and Nivolumab Combination Reduces the Risk of Disease Progression by 27% in Patients with Advanced Melanoma in Phase 3 Trial

Summary

Oral HBI-8000 plus intravenous nivolumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with nivolukab alone, reducing the risk of disease progress...